Company Overview
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +63.03% |
| 6 Months: | +124.46% |
| 3 Months: | +208.98% |
| 1 Month: | +6.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HELP Cybin D/B/A Helus Pharma PHARMA | 12.39 | -3.05 | $905.22M | 0.00% | -61.52% | -86.94% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 33.27M | 24.62M | 28.89M | 41.21M | 47.86M |
| Operating Income | - | -33.27M | -24.62M | -28.89M | -41.21M | -47.86M |
| EBITDA | - | -33.21M | -24.59M | -28.86M | -41.19M | -47.83M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -30.58M | -24.61M | -33.72M | -42.67M | -46.99M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -30.58M | -24.61M | -33.72M | -42.67M | -46.99M |
| Diluted EPS | -0.38 | - | -1.10 | -1.39 | -1.00 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | - | - | - | - |
| Gross Profit | 0 | - | - | - | - |
| Operating Expenses | - | 51.52M | 78.84M | 103.12M | 142.59M |
| Operating Income | - | -51.52M | -78.84M | -103.12M | -142.59M |
| EBITDA | - | -51.27M | -78.41M | -102.78M | -142.47M |
| Interest Expense | 0 | - | - | - | - |
| Pretax Income | - | -47.49M | -78.08M | -81.59M | -148.00M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -47.49M | -78.08M | -81.61M | -148.00M |
| Diluted EPS | -15.20 | -9.88 | -6.96 | -4.04 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 53.90M | 302.02M | 179.90M | 251.17M |
| Current Assets | - | 23.18M | 218.54M | 115.45M | 184.52M |
| Cash & Equivalents | - | 16.63M | 208.99M | 93.92M | 157.26M |
| Inventory | - | - | - | - | - |
| Receivables | - | 3.05M | 4.48M | 4.09M | 5.03M |
| Total Liabilities | - | 5.66M | 10.10M | 14.90M | 19.38M |
| Current Liabilities | - | 5.66M | 10.10M | 14.90M | 19.38M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 291.00K | 0 | - |
| Total Equity | - | 48.23M | 291.93M | 165.00M | 231.79M |
| Shares Outstanding | - | 5.15M | 20.00M | 21.61M | 51.63M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -47.43M | -68.91M | -72.33M | -133.27M |
| Investing Cash Flow | - | -3.31M | 6.92M | -1.40M | -1.36M |
| Financing Cash Flow | - | 13.56M | 254.51M | 14.10M | 198.24M |
| Capital Expenditure | - | -3.31M | -710.00K | -1.40M | -1.37M |
| Free Cash Flow | - | -50.74M | -69.62M | -73.72M | -134.64M |
| Net Change in Cash | - | -37.18M | 192.52M | -59.63M | 63.60M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -98.5% | -26.7% | -49.5% | -63.9% |
| ROCE % | - | -106.8% | -27.0% | -62.5% | -61.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Venrock Adviser, LLC | 4.89% | 3.85M | $47.64M |
| 2 | Orbimed Advisors LLC. | 4.16% | 3.27M | $40.47M |
| 3 | Adage Capital Partners GP L.L.C. | 3.89% | 3.06M | $37.85M |
| 4 | Millennium Management Llc | 3.34% | 2.63M | $32.56M |
| 5 | Rosalind Advisors, Inc. | 2.49% | 1.96M | $24.21M |
| 6 | Sphera Funds Management Ltd. | 2.06% | 1.62M | $20.05M |
| 7 | Acorn Capital Advisors, LLC | 1.96% | 1.54M | $19.05M |
| 8 | DCF Advisers, LLC | 1.82% | 1.43M | $17.75M |
| 9 | Sio Capital Management, LLC | 1.65% | 1.30M | $16.08M |
| 10 | Nan Fung Group Holdings Limited | 1.25% | 987.22K | $12.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HELP
Qualcomm issues warrants to Amazon to acquire $4 billion worth of chipmaker's stock as part of AI infrastructure deal - CNBC
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNRV8zb0t6akRzdWkxb3lvRmxFUExhc2F2Tk5EOFJURTdfTzF2M2JZSXR2LU9EQVJSVXNwSVJWLTVpa2xXQVU4VlZjU21RZ2M1QmlKekd3cDJrUnhqVjBzLS0zVVRNeUU5dE5SMXRHV1RSVTN4MlBCWFlkWFRNTUxadWxOQ3JpZUh1N3JsU9…
American Eagle Q2 Preview: Sydney Sweeney, Ella Langley, ‘Off Campus’ Partnerships Could Help Stock Rebound - tradingview.com
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxPdTAtYTQ5a0k4QURuaU5lOTNsY1RWSTFzU0h6OXRNWGZxbWtyUEQ4b1FrQVZnNFdCVDY0cnJ3T1VBZzZFQ2hNMThCQlVZVHhEX29rbV9obGJKc001QXJzSXF5ams0a2FsVXVxVGZhUGFvOV9OZUpjN0xKaHVYTTkydUM2d1hPZkZLZzlZaH…
How AI Support Rollout At Rockwell Automation Stock Has Changed Its Investment Story - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPMVg3Ml96UU1xbzZyQ1ZXX0VEdnloTlZEY3VPdkttMXRiRmdsQlpPYjBrczVGOXpqYldZSlVsQjR2bFJ0cHpvU2haeG5vckxTMS10LWNFdmFzZUNMZzZWeVRPa2xlOXl6V1ozRnBxM082cnpCRFgzQllub2V3OVVLS3E2Z2t2VDljcmMzWl…
Own Pepsi Stock? Here’s How You Can Help Bulls - People for the Ethical Treatment of Animals (PETA)
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxOX1MzMnhPakp1VTBtM21KSDM3QTVVQXBWSHBMZVM4dkFWb2hFLU44dFdiWmVZRk1LLWZ6TTRxc0lnY1VGQ2M5aXd1MVZBRFlhOU93cUIzaDE0M0FvQjhIVDkzbDNOVjFETWVtR1pPUWtBa1hMQjZUQ2VuRkNlV01zSw?oc=5" target="_…
Ridgeland community baby shower to help parents stock up on essentials - WTOC
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOZUhFX1ZUQUU0ZkxQbF9kOThBbVBwcXdQVk9WQ194a1ZXU2hwT05xMXJwN0tsbEc5VVMxRGVLNkFMV2VsUGc2d1ZZUUFKVUdXaFZaeTRzSE15bDNmUGhNOU5sX0MzRk9nMmFNaF9DWk9VWUZQVmFsUXJOX05YY3pFODNRRThJQ19zeHM5a3…
A New AI Tool Helps Investors Turn Stock-Market Chaos Into an Opportunity, Only $50 for a Lifetime Subscription - entrepreneur.com
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPSDQtQ0FaM2pyaDA4QmFDQ0xfVl96SU9qdFA0T1FDWE5RN3hSclUyTXpJRE53UlBKc2pRVnFyNW9pcXltdjdheUkzSjE2akgtR2FVVmNQazY3OGdhb2owT3hTb0ZFT1JKSC13dEhvTmJZTnVFZVpsQS13eW1KRWJBdHpyc3AyajR2eElkRG…
HELP — Frequently Asked Questions
What is the current share price of Cybin D/B/A Helus Pharma (HELP)?
As of 2026-09-19 21:16 PDT, Cybin D/B/A Helus Pharma (HELP) trades at $12.39 on NasdaqGM. Its 52-week range is $3.87 to $13.98.
What is the market capitalisation of HELP?
Cybin D/B/A Helus Pharma (HELP) has a market capitalisation of $905.22M on NasdaqGM.
What is the P/E ratio of HELP?
HELP trades at a trailing price-to-earnings (P/E) ratio of -3.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 230.78.
What is the return on equity (ROE) of HELP?
HELP has a return on equity (ROE) of -86.94%. Its return on capital employed (ROCE) is -61.52%.
Is HELP a good stock to buy?
This page provides a data-driven analysis of Cybin D/B/A Helus Pharma (HELP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.